Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

March 31, 1999 Approval Letter - Hextend, High Molecular Weight Hydroxyethyl Starch 6% (Hetastarch) in Buffered Electrolyte Dextrose Solution

Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville MD 20852--1448

March 31, 1999

OB-NDA 20-0952

BioTime, Inc.
Attention: Ronald G. Leonardi, Ph.D.
935 Pardee Street
Berkeley, CA 94710

Re: NDA 20-0952 Hextend, High Molecular Weight Hydroxyethyl Starch 6%
(Hetastarch) in Buffered Electrolyte Dextrose Solution

Dear Dr. Leonardi:

Please refer to your March 30, 1998 new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Hextend, High Molecular Weight Hydroxyethyl Starch 6% (Hetastarch) in Buffered Electrolyte Dextrose Solution.

We acknowledge receipt of your amendment dated November 27, 1998.

This application provides for the use of Hextend as a plasma volume expander for treatment of hypovolemia during surgery.

We have completed the review of this application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed marked-up draft labeling. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling must be identical to the enclosed marked-up draft labeling. Marketing the product with final printed labeling that is not identical to this draft labeling may render the product misbranded and an unapproved new drug.

Please submit sixteen copies of the final printed labeling as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy weight paper or similar material. For administrative purposes this submission should be designated "FINAL PRINTED LABELING" for approved NDA 20-0952. Approval of this submission by FDA is not required before the labeling is used.

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

Should you have any questions, please contact:
Mr. Martin Northern
301 827-3524

Sincerely yours,

-- signature --

Jay S. Epstein, M.D.
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 02/21/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English